CTKB - CIK 0001831915
Cytek Biosciences, Inc. trades as CTKB. In its fiscal 2025 annual report the company posted revenue of $201.49M, up 0.5% from the prior year and net income of -$66.54M. This page tracks Cytek Biosciences, Inc. through 432 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Cytek Biosciences, Inc.'s revenue grew from $710.00K to $201.49M, a compound annual growth rate of 209.5%. Net profit margin compressed from 2733.9% to -33.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-18 |
The largest companies sharing Cytek Biosciences, Inc.'s SEC industry classification (laboratory analytical instruments).
Cytek Biosciences, Inc. reported revenue of $201.49M for fiscal year 2025, an increase of 0.5% year over year.
In its latest fiscal year Cytek Biosciences, Inc. reported a net loss of $66.54M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.